Evaluation of the efects of inhibition Rho/Rho-kinase pathway on eosinophils from sickle cell Anemia patients and lung inflammation in sickle cell anemia mice model

Author(s)

Flávia Rubia Pallis

• Document type: Doctoral Thesis
• Press: Campinas, SP.
• Institution: Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas
• Defense date: 2015-12-02

Examining board members

Carla Fernanda Franco Penteado; Marcos Andre Cavalcanti Bezerra; Patricia Maria Bergamo Favaro; Erich Vinicius De Paula; Maria Heloisa de Souza Lima Blotta

• Advisor: Carla Fernanda Franco Penteado; Fernando Ferreira Costa

Abstract

Vaso-occlusion, comprising a complex and multicellular process, initiated by the adhesion of erythrocytes and leukocytes to the activated endothelium, leading to vascular obstruction, activation of vascular endothelial cells and continuous lesions in patients with sickle cell anemia (SCA). Preliminary results demonstrated that eosinophils from SCA patients exist in an activated state, however the participation of this cell in the vasooclusive process in not well establish. The role of proteins via the Rho GTPases in the adhesion of eosinophils to the vascular endothelium and in the pulmonary complications of SCA disease it is unknown. The aim of this study was to evaluate in vitro the role of the eosinophils and proteins belonging to the Rho GTPases family in SCA pathophysiology, and evaluate in vivo the role of this pathway in pulmonary inflammatory responses induced by OVA in SCA mice. Peripheral blood of healthy individuals (controls) and SCA patients in therapy or not with hydroxyurea (SCAHU) was collected for static and flow adhesion experiments. For static adhesion assays, eosinophils were isolated from control subjects or SCA patients on or off HU therapy. Adhesion of SCA eosinophils to HUVEC (Human Umbilical Vein Endothelial Cells) under TNF-'alfa'-stimulated conditions was higher when compared with control eosinophils, in flow conditions and static assay. Furthermore, SCAHU eosinophils demonstrated significantly lower adhesive properties, compared to SCA eosinophils. The adhesion of eosinophils from SCA or SCAHU patients were reduced when HUVEC were pretreated with NSC23766 inhibitor, compared to non-treated HUVEC. Under flow conditions, the number of eosinophils adhered to HUVEC cells was reduced when they were treated with Y-27632 or NSC23766 in the three groups investigated, however this inhibition was higher in the SCA patients. In vivo OVA induced lung inflammation, characterized by increased leukocyte particularly eosinophils, counts in the mice bronchoalveolar fuid (BALF). This inflammation was enhanced in SCA mice (Berkeley and Transplanted) when compared to controls (C57BL6). Transplanted mice showed high levels of pro-inflammatory mediators such as IL-4, IL-5, IL-6, IL-13, RANTES, Eotaxin, MCP-1, MMP-9 and TIMP-1 as compared to the control mice group (NS). Furthermore, the SCA mice induced with OVA showed higher lung gene expression of IL-6; however, there was no difference in the expression of MMP-2, MMP-8, MMP-9, MMP-12, TIMP-1 and TIMP-2, compared to NS. In the functional assessment of the bronchi reactivy, data showed that the potency to methacholine in asthmatic model was was greater in the SCA mice (Berkeley), compared to the Transplanted SCA mice, and even greater when compared to C57BL6. The animals treated with the inhibitors of the RhoA/ROCK pathway, Y-27632 or Fasudil, showed lower total and differential cells counts due to migration to the lungs. Pretreatment with the RhoA/ROCK pathway inhibitor significantly reduced the proinflammatory mediator levels evaluated. Treatment with Fasudil reduced maximal response for methacholine in bronchi from Berkeley model. No significant difference was observed in the tracheal reactivity after OVA challenge in all groups investigated. Taken together, our data indicated that RhoA/ROCK pathway play an important role in the eosinophil adhesion to the endothelium and, the inhibition of this pathway could alleviates asthma in SCA patients. Thus, we suggest that RhoA/ROCK inhibitors represents novel therapeutic agents for the treatment of SCA clinical manifestations (AU)

• FAPESP's process: 11/02380-0 - Evaluation of the effects of inhibition of the Rho/Rho-kinase in the eosinophils adhesion in patients with sickle cell anemia and in asthma experimental model in sickle mice
• Grantee: Flávia Rubia Pallis
• Support Opportunities: Scholarships in Brazil - Doctorate